These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33450024)

  • 1. A method for characterizing Cas9 variants via a one-million target sequence library of self-targeting sgRNAs.
    Tálas A; Huszár K; Kulcsár PI; Varga JK; Varga É; Tóth E; Welker Z; Erdős G; Pach PF; Welker Á; Györgypál Z; Tusnády GE; Welker E
    Nucleic Acids Res; 2021 Apr; 49(6):e31. PubMed ID: 33450024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage.
    Kulcsár PI; Tálas A; Huszár K; Ligeti Z; Tóth E; Weinhardt N; Fodor E; Welker E
    Genome Biol; 2017 Oct; 18(1):190. PubMed ID: 28985763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the sequence-specific cleavage activity of Cas9 variants.
    Kim N; Kim HK; Lee S; Seo JH; Choi JW; Park J; Min S; Yoon S; Cho SR; Kim HH
    Nat Biotechnol; 2020 Nov; 38(11):1328-1336. PubMed ID: 32514125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
    Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
    Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous evolution of SpCas9 variants compatible with non-G PAMs.
    Miller SM; Wang T; Randolph PB; Arbab M; Shen MW; Huang TP; Matuszek Z; Newby GA; Rees HA; Liu DR
    Nat Biotechnol; 2020 Apr; 38(4):471-481. PubMed ID: 32042170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blackjack mutations improve the on-target activities of increased fidelity variants of SpCas9 with 5'G-extended sgRNAs.
    Kulcsár PI; Tálas A; Tóth E; Nyeste A; Ligeti Z; Welker Z; Welker E
    Nat Commun; 2020 Mar; 11(1):1223. PubMed ID: 32144253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of genetically modified mice using SpCas9-NG engineered nuclease.
    Fujii W; Ito H; Kanke T; Ikeda A; Sugiura K; Naito K
    Sci Rep; 2019 Sep; 9(1):12878. PubMed ID: 31501500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity.
    Cerchione D; Loveluck K; Tillotson EL; Harbinski F; DaSilva J; Kelley CP; Keston-Smith E; Fernandez CA; Myer VE; Jayaram H; Steinberg BE
    PLoS One; 2020; 15(4):e0231716. PubMed ID: 32298334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient DNA interrogation of SpCas9 governed by its electrostatic interaction with DNA beyond the PAM and protospacer.
    Zhang Q; Chen Z; Wang F; Zhang S; Chen H; Gu X; Wen F; Jin J; Zhang X; Huang X; Shen B; Sun B
    Nucleic Acids Res; 2021 Dec; 49(21):12433-12444. PubMed ID: 34850124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
    Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
    Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perfectly matched 20-nucleotide guide RNA sequences enable robust genome editing using high-fidelity SpCas9 nucleases.
    Zhang D; Zhang H; Li T; Chen K; Qiu JL; Gao C
    Genome Biol; 2017 Oct; 18(1):191. PubMed ID: 29020979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo.
    Ibraheim R; Song CQ; Mir A; Amrani N; Xue W; Sontheimer EJ
    Genome Biol; 2018 Sep; 19(1):137. PubMed ID: 30231914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of target:guide homology effects on Cas9-mediated cleavage.
    Fu BX; Hansen LL; Artiles KL; Nonet ML; Fire AZ
    Nucleic Acids Res; 2014 Dec; 42(22):13778-87. PubMed ID: 25399416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.
    Maji B; Gangopadhyay SA; Lee M; Shi M; Wu P; Heler R; Mok B; Lim D; Siriwardena SU; Paul B; Dančík V; Vetere A; Mesleh MF; Marraffini LA; Liu DR; Clemons PA; Wagner BK; Choudhary A
    Cell; 2019 May; 177(4):1067-1079.e19. PubMed ID: 31051099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High fidelity CRISPR/Cas9 increases precise monoallelic and biallelic editing events in primordial germ cells.
    Idoko-Akoh A; Taylor L; Sang HM; McGrew MJ
    Sci Rep; 2018 Oct; 8(1):15126. PubMed ID: 30310080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New variants of CRISPR RNA-guided genome editing enzymes.
    Murovec J; Pirc Ž; Yang B
    Plant Biotechnol J; 2017 Aug; 15(8):917-926. PubMed ID: 28371222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein engineering of Cas9 for enhanced function.
    Oakes BL; Nadler DC; Savage DF
    Methods Enzymol; 2014; 546():491-511. PubMed ID: 25398355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient base editing with expanded targeting scope using SpCas9-NG in rabbits.
    Liu Z; Shan H; Chen S; Chen M; Song Y; Lai L; Li Z
    FASEB J; 2020 Jan; 34(1):588-596. PubMed ID: 31914687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.